Search This Blog

Monday, September 28, 2020

Eiger Bio's Lambda shows no effect in mild COVID-19 patients

Eiger BioPharmaceuticals (NASDAQ:EIGR) slips 10% premarket on light volume in reaction to results from an investigator-sponsored study evaluating Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.

Lambda, currently in late-stage development for hepatitis delta virus (HDV) infection, failed to separate from placebo as measured by SARS-CoV-2 viral shedding and time to symptom resolution.

The company in-licensed global rights to Lambda from Bristol Myers Squibb (NYSE:BMY).

https://seekingalpha.com/news/3617615-eiger-bios-lambda-shows-no-effect-in-mild-covidminus-19-patients

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.